The mission of the Florida Department of Health (FDOH) Tuberculosis Control Section (TBCS) is to eliminate tuberculosis in Florida. TBCS provides programmatic oversight, policy development, program evaluation, educational resources and training, and facilitates clinical and medical consultations to 67 county health departments throughout Florida to support all aspects of an effective TB control and prevention program. TBCS provides screening, testing, treatment, and case management services to Florida residents and visitors.
Elimination of TB in Florida is predicated on the implementation of seven priority strategies for controlling and preventing TB that include: (1) Diagnosis/treatment of persons with TB disease and persons with latent TB infection; (2) Conducting contact investigations for infectious TB cases; (3) Targeted testing for and treatment of latent TB infection (LTBI) therapy when appropriate to prevent progression to active TB; (4) Program planning, evaluation, and improvement; (5) Epidemiologic surveillance and response; (6) Human resource development and partnership activities; and (7) Public health laboratory strengthening.
TBCS is a statewide program that strives to meet or exceed the national targets for TB elimination set forth by the National TB Indicators Project (NTIP) and develops evaluation strategies to address indicators that are not being met. In addition, TBCS is committed to identifying, screening, testing, and treating individuals at high risk for exposure to Mycobacterium tuberculosis, those at high risk for progression to active TB disease if exposed, as well as populations experiencing health disparities and disproportionately affected by TB disease and LTBI.
TBCS is applying for funding under the Tuberculosis Elimination and Laboratory Cooperative Agreement CDC-RFA-PS-25-0003 to implement the strategies identified in this application. Funding for prevention, control, and laboratory strengthening will allow for continued and new activities that will be measured by evaluation of progress toward short and intermediate-term outcomes outlined in the funding announcement. Progress toward these outcomes will lead to a decreased TB incidence overall and among populations at higher risk for TB disease and LTBI.